IBD
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →Vedolizumab trough concentrations and clinical and endoscopic outcomes in inflammatory bowel disease: a systematic review and meta-analysis.
Clinical takeawayHigher vedolizumab trough concentrations are associated with remission, but prospective trials are needed before considering proactive therapeutic drug monitoring in UC and CD.
What it foundHigher vedolizumab trough concentrations were associated with endoscopic remission in UC (mean difference 4.86 μg/mL, 95% CI 2.75-6.98) and clinical remission in both UC (3.18 μg/mL) and CD (3.08 μg/mL), but not endoscopic remission in CD (1.40 μg/mL, p=0.453).
ContextConfirms and quantifies prior observational data on vedolizumab TDM, but highlights uncertainty due to cross-sectional design and lack of CD endoscopic association. The cross-sectional nature limits causal inference.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Soliman MA … Papamichael K · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗